drug-eluting balloons, DEB, ECRI, report, peripheral artery disease, PAD, cath

ECRI Institute has created a report that offers an overview of drug-eluting balloon (DEB) technology, “Health Technology Forecast report, "Drug-eluting Angioplasty Balloons for Preventing Restenosis after Revascularization." The report details some of the key questions regarding DEBs.

SynCardia Systems Inc. has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the effectiveness of the SynCardia temporary Total Artificial Heart for permanent use, also called destination therapy.

Pamela Woodard, nanoparticle, Washington University, PET scan, plaque

The U.S. Food and Drug Administration (FDA) has approved for human evaluation a nanoparticle-based imaging agent jointly developed at Washington University School of Medicine in St. Louis and the University of California, Santa Barbara, in collaboration with Texas A&M University.

Medtronic announced new results from the PainFree SST and Shock-Less clinical studies published in the journal HeartRhythm.

Merge Healthcare Inc. announced that Merge Cardio has been named Best in KLAS for the cardiology software category in the "2014 Best in KLAS: Software & Services" report. In addition, Merge Hemo has been named the KLAS Category Leader in Cardiology Hemodynamics. This marks the second and fourth consecutive wins for Merge Cardio and Merge Hemo, respectively.

The 2014 Best in KLAS report ranks healthcare vendors and their solutions by the professionals who use them—healthcare providers.

CardioKinetix, Parachute, Heart failure
Sunshine Heart C-Pulse
CardioFit vagus nerve stimulator
CardioKinetix, Parachute
DC Devices, intra-arterial shunt device, IASD
St. Jude Medical, SJM, CardioMems

There are several new interventional and minimally invasive surgical heart failure (HF) devices in development or in trials that might offer new ways to boost patient volume in the coming years. There is a lot of potential economic opportunity in new HF therapies, since HF represents the single-largest cause of hospitalizations in many countries and it is the largest expense in the U.S. Medicare budget. 

Medtronic revealed new one-year clinical data showing that transcatheter aortic valve replacement (TAVR) with the self-expanding CoreValve System offers advantages in survival and safety compared to surgical aortic valve replacement (SAVR) in high risk aortic stenosis patients who have previously undergone coronary artery bypass grafting (CABG) surgery. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now